Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04902768 · ClinicalTrials.gov registry record

Assessment of Patterns of Patient Reported Outcomes in Adults With Congenital Heart Disease - International Study II

A clinical trial of Congenital Heart Disease, sponsored by KU Leuven.

Completed
Registry status
8,415
Enrollment target
20
Study locations

NCT04902768: Completed study of Congenital Heart Disease, sponsored by KU Leuven.

NCT04902768 is a study of Congenital Heart Disease that has completed, run by KU Leuven. The registered enrollment target is 8,415 participants, above the 340-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (2375% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04902768, a study of Congenital Heart Disease, has completed, sponsored by KU Leuven.

COMPLETED
Registry status
8,415 participants
Enrollment target
20
Study locations

Study Summary

This is an international, cross-sectional and descriptive study that aims to investigate differences in patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) and that aims to explore the profile and healthcare needs of adults with congenital heart diseases.

Primary Outcome

This outcome is measured using the shortened version of the RAND-36. Composite physical (PCS) and mental health (MCS) scores are computed. Scores range from 0 (lowest health level) to 100 (highest health level).

Conditions Studied

Interventions

  • OTHER This is an observational study, there is no intervention

Study Locations (20)

Other

  • Hospital San Juan De Dios De La Plata - Buenos Aires
  • Hospital de Niños - Córdoba
  • Melbourne Children's Cardiology - Melbourne
  • Vienna General Hospital - Vienna
  • Ghent University Hospital - Ghent
  • University Hospitals Leuven - Leuven
  • Princess Marina Hospital - Gaborone
  • Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - Ribeirão Preto
  • National Heart Hospital - Sofia
  • Clinique Medical Le Jourdain - Yaoundé

California

  • University of California - San Francisco
  • Lucile Packard Children's Hospital and Stanford Health Care - Stanford

Florida

  • University of Florida Health - Gainesville

Maryland

  • Taussig Heart Center of Johns Hopkins Hospital - Baltimore

Massachusetts

  • Boston Children's / Brigham and Women's - Boston

New York

  • Mount Sinai Heart - New York

Ohio

  • Nationwide Children's Hospital - Columbus

Oregon

  • Oregon Health and Science University - Portland

Trial Details

FieldValue
Enrollment Target 8,415 participants
Start Date 2019-08-01
Est. Completion 2022-12-31
KU Leuven

1 total trials

What the finished NCT04902768 record still lists

NCT04902768 is an observational study that tracks outcomes without assigning an intervention. Its 8,415 participants enrollment target places it among the larger protocols in the corpus, above the 340-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (2375% higher).

The record links to 1 condition, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which This is an observational study, there is no intervention is the first listed.

NCT04902768 names 20 study sites across 10 states, led by Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04902768 about?

NCT04902768 is a clinical study titled "Assessment of Patterns of Patient Reported Outcomes in Adults With Congenital Heart Disease - International Study II". This is an international, cross-sectional and descriptive study that aims to investigate differences in patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) and that aims to explore the profile and healthcare needs of adults with congenital heart diseases.

What is the current status of trial NCT04902768?

This trial is currently completed. The enrollment target is 8,415 participants. The study started on 2019-08-01. Estimated completion is 2022-12-31.

What conditions does trial NCT04902768 study?

This clinical trial studies the following conditions: Congenital Heart Disease.

What interventions are being tested in trial NCT04902768?

The interventions under investigation include: This is an observational study, there is no intervention (OTHER).

Who is sponsoring clinical trial NCT04902768?

This trial is sponsored by KU Leuven, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04902768 being conducted?

This trial has 20 study locations across California, Florida, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04902768's enrollment target sits among peer trials

8,415 1st of 63 higher than 63 of 63 other Congenital Heart Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07185828 · 8,286 participants · NA

    Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)

  • NCT06098079 · 8,600 participants · Phase 4

    Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

  • NCT06435806 · 8,200 participants · NA

    Medical Illustration Design Characteristic Evaluation

  • NCT06058234 · 8,680 participants

    Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04902768, the US trial registry maintained by the National Library of Medicine. NCT04902768 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.